| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615747 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 7 Pages |
Abstract
Long-term outcomes with VcR-CVAD are comparable with more intensive inductions and consolidation approaches. MCL is biologically heterogeneous, and durable remission can be achieved with intermediate intensity therapy. MR appears to contribute to these excellent outcomes.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Julie E. Chang, Lakeesha L. Carmichael, KyungMann Kim, Christopher Peterson, David T. Yang, Anne M. Traynor, Jae E. Werndli, Michael S. Huie, Thomas A. McFarland, Michael Volk, Jules Blank, Natalie S. Callander, Walter L. Longo, Brad S. Kahl,